Therapeutic proteasome inhibition in experimental acute pancreatitis

Research output: Contribution to journalArticle

8 Citations (Scopus)


Aim: To establish the therapeutic potential of proteasome inhibition, we examined the therapeutic effects of MG132 (Z-Leu-Leu-Leu-aldehyde) in an experimental model of acute pancreatitis. Methods: Pancreatitis was induced in rats by two hourly intraperitoneal (ip) injections of cholecystokinin octapeptide (CCK; 2 × 100 μg/ kg) and the proteasome inhibitor MG132 (10 mg/kg ip) was administered 30 min after the second CCK injection. Animals were sacrificed 4 h after the first injection of CCK. Results: Administering the proteasome inhibitor MG132 (at a dose of 10 mg/kg, ip) 90 min after the onset of pancreatic inflammation induced the expression of cell-protective 72 kDa heat shock protein (HSP72) and decreased DNA-binding of nuclear factor-κB (NF-κB). Furthermore MG132 treatment resulted in milder inflammatory response and cellular damage, as revealed by improved laboratory and histological parameters of pancreatitis and associated oxidative stress. Conclusion: Our findings suggest that proteasome inhibition might be beneficial not only for the prevention, but also for the therapy of acute pancreatitis.

Original languageEnglish
Pages (from-to)4452-4457
Number of pages6
JournalWorld journal of gastroenterology
Issue number33
Publication statusPublished - Sep 7 2007


  • Acute pancreatitis
  • Cholecystokinin octapeptide
  • Heat shock proteins
  • Nuclear factor-κB
  • Proteasome inhibition

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Therapeutic proteasome inhibition in experimental acute pancreatitis'. Together they form a unique fingerprint.

  • Cite this